The article highlights the author's successful 17-year journey with clozapine, a medication that led to their full recovery from severe psychosis while discussing the widespread underutilization of this treatment. Despite its efficacy for treatment-resistant psychosis, only about one in 50 qualifying patients access clozapine due to restrictive barriers such as the Risk Evaluation and Mitigation Strategy program. The author expresses concern over these limitations and the negative impact on patients who could benefit from clozapine, emphasizing the need for a reevaluation of current prescribing practices to improve access.
Clozapine transformed my life, taking me from disability to independence, yet its underutilization due to restrictive protocols limits access for those who need it most.
Despite qualifying, only about one in 50 Americans can access clozapine, revealing a significant barrier in treatment options for those with severe mental illness.
Collection
[
|
...
]